TEXTRON INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TEXTRON INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $14.80B | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $13.70B | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | $13.68B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $12.87B | Feb 6, 2025 |
| FY2023 | Jan 1, 2022 | $12.38B | Feb 12, 2024 |
| FY2020 | Jan 2, 2021 | $3.67B | Feb 19, 2021 |
| FY2020 | Oct 3, 2020 | $2.74B | Feb 19, 2021 |
| FY2020 | Jul 4, 2020 | $2.47B | Feb 19, 2021 |
| FY2020 | Apr 4, 2020 | $2.78B | Feb 19, 2021 |
| FY2020 | Jan 4, 2020 | $4.04B | Feb 19, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jan 4, 2020 | $13.63B | Feb 25, 2020 |
| FY2019 | Dec 29, 2018 | $13.97B | Feb 25, 2020 |
| FY2019 | Dec 30, 2017 | $14.20B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $13.79B | Feb 14, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $14.13B | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $13.71B | Feb 15, 2018 |
| FY2017 | Jan 2, 2016 | $13.34B | Feb 15, 2018 |
| FY2016 | Jan 3, 2015 | $13.78B | Feb 22, 2017 |
| FY2015 | Dec 28, 2013 | $11.97B | Feb 24, 2016 |
| FY2014 | Dec 29, 2012 | $12.02B | Feb 25, 2015 |
| FY2013 | Dec 31, 2011 | $11.17B | Feb 14, 2014 |
| FY2012 | Jan 1, 2011 | $10.31B | Feb 15, 2013 |
| FY2011 | Jan 2, 2010 | $10.14B | Feb 23, 2012 |
| FY2010 | Jan 3, 2009 | $13.29B | Mar 1, 2011 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $921.00M | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $824.00M | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | $921.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $861.00M | Feb 6, 2025 |
| FY2023 | Jan 1, 2022 | $746.00M | Feb 12, 2024 |
| FY2022 | Jan 2, 2021 | $309.00M | Feb 16, 2023 |
| FY2021 | Jan 4, 2020 | $815.00M | Feb 17, 2022 |
| FY2018 | Dec 29, 2018 | $246.00M | Feb 14, 2019 |
| FY2018 | Sep 29, 2018 | $563.00M | Feb 14, 2019 |
| FY2018 | Jun 30, 2018 | $224.00M | Feb 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $521.00M | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $491.00M | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | $570.00M | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $601.00M | Feb 6, 2025 |
| FY2023 | Jan 1, 2022 | $619.00M | Feb 12, 2024 |
| FY2022 | Jan 2, 2021 | $549.00M | Feb 16, 2023 |
| FY2021 | Jan 4, 2020 | $647.00M | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $643.00M | Feb 19, 2021 |
| FY2019 | Dec 30, 2017 | $634.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $677.00M | Feb 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.17B | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $1.16B | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | $1.23B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.19B | Feb 6, 2025 |
| FY2023 | Jan 1, 2022 | $1.22B | Feb 12, 2024 |
| FY2022 | Jan 2, 2021 | $1.05B | Feb 16, 2023 |
| FY2021 | Jan 4, 2020 | $1.15B | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $1.28B | Feb 19, 2021 |
| FY2019 | Dec 30, 2017 | $1.33B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.32B | Feb 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $1.31B | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $1.01B | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | $1.27B | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | $1.49B | Feb 6, 2025 |
| FY2023 | Jan 1, 2022 | $1.60B | Feb 12, 2024 |
| FY2022 | Jan 2, 2021 | $768.00M | Feb 16, 2023 |
| FY2021 | Jan 4, 2020 | $1.01B | Feb 17, 2022 |
| FY2020 | Dec 29, 2018 | $1.11B | Feb 19, 2021 |
| FY2019 | Dec 30, 2017 | $936.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $925.00M | Feb 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $18.13B | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $16.84B | Feb 11, 2026 |
| FY2024 | Dec 30, 2023 | $16.86B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $16.29B | Feb 12, 2024 |
| FY2022 | Jan 1, 2022 | $15.83B | Feb 16, 2023 |
| FY2021 | Jan 2, 2021 | $15.44B | Feb 17, 2022 |
| FY2020 | Jan 4, 2020 | $15.02B | Feb 19, 2021 |
| FY2019 | Dec 29, 2018 | $14.26B | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $15.34B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $15.36B | Feb 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $10.25B | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $9.63B | Feb 11, 2026 |
| FY2024 | Dec 30, 2023 | $9.87B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $9.18B | Feb 12, 2024 |
| FY2022 | Jan 1, 2022 | $9.01B | Feb 16, 2023 |
| FY2021 | Jan 2, 2021 | $9.60B | Feb 17, 2022 |
| FY2020 | Jan 4, 2020 | $9.50B | Feb 19, 2021 |
| FY2019 | Dec 29, 2018 | $9.07B | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $9.69B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $9.78B | Feb 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $7.88B | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $7.20B | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | $6.99B | Feb 11, 2026 |
| FY2025 | Dec 31, 2022 | $7.11B | Feb 11, 2026 |
| FY2024 | Jan 1, 2022 | $6.82B | Feb 6, 2025 |
| FY2023 | Jan 2, 2021 | $5.85B | Feb 12, 2024 |
| FY2022 | Jan 4, 2020 | $5.52B | Feb 16, 2023 |
| FY2021 | Dec 29, 2018 | $5.19B | Feb 17, 2022 |
| FY2020 | Dec 30, 2017 | $5.65B | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | $5.57B | Feb 25, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | $5.78B | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | $5.61B | Feb 11, 2026 |
| FY2024 | Dec 30, 2023 | $5.86B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $5.90B | Feb 12, 2024 |
| FY2022 | Jan 1, 2022 | $5.87B | Feb 16, 2023 |
| FY2021 | Jan 2, 2021 | $5.97B | Feb 17, 2022 |
| FY2020 | Jan 4, 2020 | $5.68B | Feb 19, 2021 |
| FY2019 | Dec 29, 2018 | $5.41B | Feb 25, 2020 |
| FY2018 | Dec 30, 2017 | $5.37B | Feb 14, 2019 |
| FY2017 | Dec 31, 2016 | $5.55B | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 30, 2017 | $1.26B | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $1.30B | Feb 15, 2018 |
| FY2017 | Jan 2, 2016 | $1.01B | Feb 15, 2018 |
| FY2017 | Jan 3, 2015 | $822.00M | Feb 15, 2018 |
| FY2016 | Dec 28, 2013 | $1.21B | Feb 22, 2017 |
| FY2015 | Dec 29, 2012 | $1.41B | Feb 24, 2016 |
| FY2014 | Dec 31, 2011 | $885.00M | Feb 25, 2015 |
| FY2013 | Jan 1, 2011 | $931.00M | Feb 14, 2014 |
| FY2012 | Jan 2, 2010 | $1.89B | Feb 15, 2013 |
| FY2011 | Jan 3, 2009 | $547.00M | Feb 23, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 5 | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | 4 | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | 4 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 6, 2025 |
| FY2023 | Jan 1, 2022 | 3 | Feb 12, 2024 |
| FY2018 | Dec 29, 2018 | 1 | Feb 14, 2019 |
| FY2018 | Sep 29, 2018 | 2 | Feb 14, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 14, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Feb 14, 2019 |
| FY2018 | Dec 30, 2017 | 0 | Feb 14, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 5 | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | 4 | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | 4 | Feb 11, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 6, 2025 |
| FY2023 | Jan 1, 2022 | 3 | Feb 12, 2024 |
| FY2018 | Dec 29, 2018 | 1 | Feb 14, 2019 |
| FY2018 | Sep 29, 2018 | 2 | Feb 14, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 14, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Feb 14, 2019 |
| FY2018 | Dec 30, 2017 | 0 | Feb 14, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 3, 2026 | 174.31M | Feb 11, 2026 |
| FY2025 | Dec 28, 2024 | 182.96M | Feb 11, 2026 |
| FY2025 | Dec 30, 2023 | 192.90M | Feb 11, 2026 |
| FY2025 | Dec 31, 2022 | 206.16M | Feb 11, 2026 |
| FY2024 | Jan 1, 2022 | 216.94M | Feb 6, 2025 |
| FY2023 | Jan 2, 2021 | 226.44M | Feb 12, 2024 |
| FY2022 | Jan 4, 2020 | 227.96M | Feb 16, 2023 |
| FY2021 | Dec 29, 2018 | 235.62M | Feb 17, 2022 |
| FY2020 | Dec 30, 2017 | 261.47M | Feb 19, 2021 |
| FY2019 | Dec 31, 2016 | 270.29M | Feb 25, 2020 |